Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy

HIV Clinical Trials

Volumn 4, Issue 1, 2003, Pages 1-10

  Asboe, David ^a   Mandalia, S ^a   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Nonnucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 0037228452     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/P19C-CCEK-R62L-1G91     Document Type: Article

References (15)

1. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13(6):F35-43.
2. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2(4):276-313.
3. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther. 2000;5(1):41-48.
4. Gulick RM, Hu XJ, Fiscus SA, et al. Randomised study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency Virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359. J Infect Dis. 2000;182:1375-1384.
5. Hammer S, Squires K, Degruttola V, et al. Randomised trial of ABC, and nelfinavir in combination with efavirenz and adefovir dipivoxil as salvage therapy inpatients with virologic failure receiving indinavir. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; Chicago; Jan. 31-Feb. 4, 1999. Abstract 490.
6. Shulman NS, Zolopa RA, Passaro DJ, et al. Efavirenz and adefovir dipivoxil based salvage therapy in highly treatment experienced patients: clinical and genotypic predictors of virologic response. J AIDS. 2000;23:221-226.
7. Hammer SM, Vaida F, Bennett KK, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomised trial. JAMA. 2002;288(2):239-241.
8. Carmena J, Ricart C, Jordan M, Vicente R, Perez C, Alcaraz MJ, Leon P. Observational protease inhibitor salvage study, using efavirenz plus two new nucleoside reverse transcriptase inhibitors. In: Program and abstracts of the Seventh Annual Meeting of the British HIV Association; April 2001; Brighton. Abstract P33.
9. Albrecht MA, Bosch RJ, Liou SH, Katzenstein D. ACTG 364: efficacy of nelfinavir (NFV and/or efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects: week 144 results. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 425-W.
10. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs nevirapine comparison): a randomised, open label study in HIV infected naäive individuals. HIV Clin Trials. 2002;3(3):186-194.
11. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly anti-retroviral-experienced patients. AIDS. 2001;15:2385-2395.
12. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in anti-retroviral-naïve patients: a cohort study. AIDS. 2002;16:53-61.
13. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002;185(8):1062-1069.
14. Keiser P, Nassar N, White C, Koen G, Moreno S. Cohort study shows treatment advantage across many risk factors for efavirenz vs. nevirapine-containing regimens in treatment-naïve HIV-1 infected individuals. In: Late breaker program of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; 2001; Athens, Greece.
15. Fischl M, Greenberg S, Clumeck N, et al. Ziagen combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naïve subjects (CNAA 3003). In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago. Abstract 19.